One should hold Ranbaxy Laboratories in the portfolio and from current level it can go to Rs 475, says Atul Badkar, VP - Institutional Equities - Derivatives Desk at Edelweiss Securities.

Check Out: Super Six stocks for May 15

Rakesh Gandhi of FRR Shares is bullish on Ranbaxy Laboratories and recommended to buy around Rs 450 with a stop loss of Rs 430 and short-term target of Rs 470.

Prefer Dr Reddys, Sun Pharma: Suresh Mahadevan

One can prefer Dr Reddys Laboratories, Sun Pharma over Ranbaxy, says Suresh Mahadevan, MD & Head of Indian Equities at UBS Securities.

Hold Ranbaxy, target of Rs 509: Sharmila Joshi

Sharmila Joshi, Head of Equity of Peerless Securities said she would hold Ranbaxy for the time being. She expects the stock to hit Rs 509 in next six to nine months.

Book profits in Ranbaxy Labs: Daljeet Kohli

Daljeet Kohli, Head of Research at IndiaNivesh Securities Private Limited advised booking profits in Ranbaxy Labs.

Buy Ranbaxy Laboratories, says Sukhani

According to Sudarshan Sukhani of s2analytics.com, positional traders should buy Ranbaxy Laboratories and hold it for a few weeks. He feels after a consolidation of many days Ranbaxy is probably now willing to go higher again.

Buy Ranbaxy 460 Call at around Rs 5.5: HDFC Securities

According to VK Sharma of HDFC Securities, if one buys Ranbaxy 460 Call at around Rs 5.5 and keep a stop loss at Rs 2 it would be possible to earn a premium of Rs 7.

F&O cues: VK Sharma positive on IDBI Bank, Ranbaxy

VK Sharma, fundamental analyst, HDFC Securities, recommends buying IDBI Bank and Ranbaxy Laboratories.

Do not see secular upside in Ranbaxy: Pathiparampil

Bino Pathiparampil of IIFL says he does not see a secular upside in Ranbaxy Labs even at these levels. According to him, the stock continues to be expensive even after the underperformance.

Buy Ranbaxy advises Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com recommended buying Ranbaxy Laboratories.

Buy Ranbaxy Laboratories: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ranbaxy Laboratories.

Short Ranbaxy Labs with a target of Rs 418: Bhamre

Siddharth Bhamre of Angel Broking is of the view that one can short Ranbaxy Laboratories with a target of Rs 418.

6 stocks likely to see lot of action today

On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, manasjaiswal.com, Manav Chopra, Nirmal Bang and Rakesh Gandhi, FRR share, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Ranbaxy Labs, Dr Reddy Labs good bets: Vora

Ranbaxy Labs and Dr Reddy Labs are good bets in pharma space, says Amisha Vora, Prabhudas Lilladher.

Buy Ranbaxy Laboratories: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ranbaxy Laboratories.

Super Six short term picks for March 28

On CNBC-TV18's show Super Six, market gurus Vishal Malkan, malkansview.com, Vishal Kshatriya, Edelweiss and Vikrant Jadeja, vibranttrades.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Hold Ranbaxy for medium to long term: Tater

Aashish Tater, Head of Research at Fortunewizard.com advised holding Ranbaxy Labs from a medium to long term perspective.

Buy TCS, Ranbaxy, says Rahul Mohindar

Rahul Mohindar of Viratechindia advised buying TCS and Ranbaxy Laboratories. He feels these stocks might see upside of 5-6 percent.

Buy Ranbaxy Laboratories: Panda

Jitendra Panda, Capital First Securities is of the view that one can buy Ranbaxy Laboratories at current levels.

Buy Ranbaxy Laboratories on dips: Sukhani

One can buy Ranbaxy Laboratories on dips, says Sudarshan Sukhani of s2analytics.com.

Buy Cipla, Ranbaxy, HUL on dips: Sukhani

Sudarshan Sukhani of s2analytics.com advises trader to buy Cipla, Ranbaxy and HUL on dips.

Buy Ranbaxy Laboratories: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ranbaxy Laboratories.

Expect Ranbaxy to test Rs 440: Badkar

Atul Badkar of Edelweiss Securities feels Rs 440 is very easily achievable with a stop loss of Rs 412 on Ranbaxy Laboratories.

Expect 10-15% rise in Ranbaxy in long term: Sekhar

Phani Sekhar, Fund Manager of Angel Broking expects another 10-15 percent appreciation in Ranbaxy from a longer term perspective.

Ranbaxy Labs can go upto Rs 430-440: Parag Doctor

Parag Doctor, Head - Trading Strategies, Keynote Capital's Ltd is of the view that Ranbaxy Laboratories can go upto Rs 430-440.